Skip to main content
Clinical Trials/NCT00000179
NCT00000179
Completed
Phase 3

Agitation in Alzheimer's Disease

National Institute on Aging (NIA)16 sites in 1 countryNovember 1, 1999

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Alzheimer Disease
Sponsor
National Institute on Aging (NIA)
Locations
16
Status
Completed
Last Updated
20 years ago

Overview

Brief Summary

Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.

Registry
clinicaltrials.gov
Start Date
November 1, 1999
End Date
TBD
Last Updated
20 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
National Institute on Aging (NIA)

Eligibility Criteria

Inclusion Criteria

  • Memory problem consistent with a probable diagnosis of Alzheimer's disease (AD)
  • Agitation symptoms for at least the past 2 weeks
  • Patient has caregiver who can participate
  • Patient lives in the same household as the caregiver

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (16)

Loading locations...

Similar Trials